Skip to main content
SpringerLink
Log in
Book cover

Neoplastic Diseases of the Blood pp 135–152Cite as

Hairy Cell Leukemia

  • Chapter
  • First Online:

Abstract

The WHO categorizes hairy cell leukemia (HCL) as a mature B-cell neoplasm. HCL is characterized by lymphocytes with prominent cytoplasmic projections (hairy cells) infiltrating the bone marrow and spleen, leading to pancytopenia, bone marrow fibrosis, and splenic enlargement. Hairy cells have a unique immunophenotypic profile—CD11c+, CD20+, CD25+, and CD103+—that confirms its diagnosis. The course of HCL is usually chronic, but can often be progressive, and most patients require treatment at some point. The purine nucleoside analogues, pentostatin and cladribine, are highly active, but cladribine is the preferred first-line choice due to its efficacy, brief treatment duration, and favorable toxicity profile. Other therapeutic options include rituximab, interferon-alpha, vemurafenib, and splenectomy. With current therapy, an overall survival of 87% at 12 years has been reported.

This is a preview of subscription content, log in via an institution.

References

  1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609–30.

    CAS  PubMed  Google Scholar 

  2. Schreck R, Donnelly WJ. Hairy cells in blood in lymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. Blood. 1966;27:199–211.

    Google Scholar 

  3. Anderson KC, Boyd AW, Fisher DC, et al. Hairy cell leukemia: a tumor of pre-plasma cells. Blood. 1986;65:620–9.

    Google Scholar 

  4. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2003;199:59–68.

    Article  CAS  Google Scholar 

  5. Flandrin G, Sigaux F, Sebahoun G, et al. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol. 1984;11:458–71.

    CAS  PubMed  Google Scholar 

  6. Dores GM, Matsuno RK, Weisenburger DD, et al. Hairy cell leukaemia: a heterogeneous disease. Br J Haematol. 2008;142:45–51.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Oleske D, Golomb HM, Farber MD, et al. A case control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol. 1985;121:675–83.

    Article  CAS  PubMed  Google Scholar 

  8. Orsi L, Delabre L, Monnereau A, et al. Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. Occup Environ Med. 2009;66:291–8.

    Article  CAS  PubMed  Google Scholar 

  9. Wolf BC, Martin AW, Neiman RS. The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization. Am J Pathol. 1990;136:717–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Wachsman W, Golde DW, Chen IS. Hairy cell leukemia and human T cell leukemia virus. Semin Oncol. 1984;11:446–50.

    CAS  PubMed  Google Scholar 

  11. Makower D, Marino P, Frank M, et al. Familial hairy cell leukemia. Leuk Lymphoma. 1998;29:193–7.

    Article  CAS  PubMed  Google Scholar 

  12. Colovic MD, Jankovic GM, Wiernik PH. Hairy cell leukemia in first cousins and review of the literature. Eur J Haematol. 2001;67:185–8.

    Article  CAS  PubMed  Google Scholar 

  13. Cawley JC. The pathophysiology of the hairy cell. Hematol Oncol Clin North Am. 2006;20:1011–21.

    Article  CAS  PubMed  Google Scholar 

  14. Capello D, Vitolo U, Pasqualucci L, et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasms. Blood. 2000;95:651–9.

    CAS  PubMed  Google Scholar 

  15. Forconi F, Sahota S, Raspadori D, et al. Tumor cells of hairy cell leukemia expresses multiple clonally related immunoglobulin isotypes via RNA splicing. Blood. 2001;98:1174–81.

    Article  CAS  PubMed  Google Scholar 

  16. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20:1051–63.

    Article  PubMed  Google Scholar 

  17. Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood. 1994;83:497–504.

    CAS  PubMed  Google Scholar 

  18. Burthem J, Baker PK, Hunt JA, et al. Hairy cell interactions with extracellular matrix:expression of specific integrin receptors and their role in the cell’s response to specific adhesive proteins. Blood. 1994;84:873–82.

    CAS  PubMed  Google Scholar 

  19. Aziz KA, Till KJ, Zuzel M, et al. Involvement of CD 44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood. 2000;96:3161–7.

    CAS  PubMed  Google Scholar 

  20. Nanba K, Soban E, Bowling M. Splenic pseudosinuses and hepatic angiomatous lesions. Am J Clin Pathol. 1977;67:415–26.

    Article  CAS  PubMed  Google Scholar 

  21. Haglund U, Juliusson G, Birgitta S, et al. Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions. Blood. 1994;83:2637–45.

    CAS  PubMed  Google Scholar 

  22. Sambani C, Trafalis DT, Mitsoulis-Mentzikoff C, et al. Clonal chromosome rearrangements in hairy cell leukemia: personal experience and review of literature. Cancer Genet Cytogenet. 2001;129:138–44.

    Article  CAS  PubMed  Google Scholar 

  23. Anderson CL, Gruszka-Westwood A, Ostergaard M, et al. A marrow deletion of 7q is common to HCL and SMZL, but not CLL. Eur J Haematol. 2004;72:390–402.

    Article  Google Scholar 

  24. Vallianatou K, Brito-Babapulle V, Matutes E, et al. P53 gene deletion and trisomy 12 in hairy cell leukemia and its variant. Leuk Res. 1999;23:1041–5.

    Article  CAS  PubMed  Google Scholar 

  25. Burke JS. The value of the bone marrow biopsy in the diagnosis of hairy cell leukemia. Am J Clin Pathol. 1978;70:876–84.

    Article  CAS  PubMed  Google Scholar 

  26. Sharpe RW, Bethel KJ. Hairy cell leukemia: diagnostic pathology. Hematol Oncol Clin North Am. 1996;20:1023–49.

    Article  Google Scholar 

  27. Zuzel M, Cawley JC. The biology of hairy cells. Best Pract Res Clin Haematol. 2003;16:1–13.

    Article  CAS  PubMed  Google Scholar 

  28. Cawley JC. What is the nature of the hairy cell and why should we be interested? Br J Haematol. 1997;97:511–4.

    Article  PubMed  Google Scholar 

  29. Rosner MC, Golomb HM. Ribosome-lamella complex in hairy cell leukemia: ultrastructure and distribution. Lab Investig. 1980;42:236–47.

    CAS  PubMed  Google Scholar 

  30. Brunning RD, Parkin J. Ribosome-lamella complexes in neoplastic hematopoietic cells. Am J Pathol. 1975;79:565–78.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Katayama I, Li Y, Tam LT. Ultrastructural characteristics of the “hairy cells” of leukemic reticuloendotheliosis. Am J Pathol. 1972;67:361–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med. 1971;284:357–60.

    Article  CAS  PubMed  Google Scholar 

  33. Li CY, Yam LT, Lam KW. Studies of acid phosphatase isoenzymes in human leukocytes demonstration of isoenzyme cell specificity. J Histochem Cytochem. 1970;19:901–10.

    Article  Google Scholar 

  34. Bartl R, Frisch B, Hill W, et al. Bone marrow histology in hairy cell leukemia. Identification of subtype and their prognosis. Am J Clin Pathol. 1983;79:531–45.

    Article  CAS  PubMed  Google Scholar 

  35. Krause JR. Aplastic anemia terminating in hairy cell leukemia. A report of two cases. Cancer. 1984;53:1533–7.

    Article  CAS  PubMed  Google Scholar 

  36. Turner A, Kjeldsberg CR. Hairy cell leukemia: a review. Medicine. 1978;57:477–99.

    Article  CAS  PubMed  Google Scholar 

  37. Tiacci E, Trionov V, Shiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Jain P, Ok CY, Konoplev S, et al. Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia: a distinct entity? J Clin Oncol. 2016;34(7):e57–60.

    Article  CAS  PubMed  Google Scholar 

  39. Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119:3330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP 2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8.

    Article  CAS  PubMed  Google Scholar 

  41. Rossi D, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209:1537–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP 2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655–8.

    Article  CAS  PubMed  Google Scholar 

  43. Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol. 2003;119:213–7.

    Article  PubMed  Google Scholar 

  44. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82:1277–87.

    CAS  PubMed  Google Scholar 

  45. Golomb HM, Hadad LJ. Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol. 1984;16:393–401.

    Article  CAS  PubMed  Google Scholar 

  46. Burns GF, Cawley JC, Karpas WA, et al. Multiple heavy chain isotypes on the surface of the cells of hairy cell leukemia. Blood. 1978;52:1132–47.

    CAS  PubMed  Google Scholar 

  47. Kluin-Nelemans HC, Krouwels MM, Jansen JH, et al. Hairy cell leukemia preferentially expresses the IgG3-subclass. Blood. 1990;75:972–5.

    CAS  PubMed  Google Scholar 

  48. Hanson CA, Gribbon TE, Schnitzer B, et al. CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. Blood. 1990;76:2360–7.

    CAS  PubMed  Google Scholar 

  49. Visser L, Shaw A, Slupsky J, et al. Monoclonal antibodies reactive with hairy cell leukemia. Blood. 1989;74:320–5.

    CAS  PubMed  Google Scholar 

  50. Flenghi L, Spinozzi F, Stein H, et al. LF61: a new monoclonal antibody directed against a trimeric molecule (150 kDa, 125 kDa, 105 kDa) associated with hairy cell leukemia. Br J Haematol. 1990;76:451–9.

    Article  CAS  PubMed  Google Scholar 

  51. Dong HY, Weisberger J, Liu Z, et al. Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics. Am J Clin Pathol. 2009;131:586–95.

    Article  CAS  PubMed  Google Scholar 

  52. Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994, 14(Suppl 1):57–61.

    Google Scholar 

  53. Quigley MM, Bethel KJ, Sharpe RW, et al. CD52 expression in hairy cell leukemia. Am J Hematol. 2003;74(4):227–30.

    Article  CAS  PubMed  Google Scholar 

  54. Del Giudice I, Matutes E, Morilla R, et al. The diagnostic value of CD 123 in B cell disorders with hairy or villous lymphocytes. Haematologica. 2004;89:303–8.

    PubMed  Google Scholar 

  55. Munoz L, Nomededeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD 123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261–9.

    CAS  PubMed  Google Scholar 

  56. Shao H, Calvo KR, Grönborg M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res. 2013;37:401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hounieu H, Chittal SM, Saati TA, et al. Hairy cell leukemia. Diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol. 1992;98:26–33.

    Article  CAS  PubMed  Google Scholar 

  58. Janckila AJ, Cardwell EM, Yam LT, et al. Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase. Blood. 1995;85:2939–44.

    Google Scholar 

  59. Saati TA, Caspar S, Brousset P, et al. Production of anti-B monoclonal antibodies (DBB.44, DBA.44, DNA.7, and DND.53) reactive on paraffin-embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice. Blood. 1989;74:2476–85.

    PubMed  Google Scholar 

  60. Went PT, Zimpfer A, Pehrs AC, et al. High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. Am J Surg Pathol. 2005;29:474–8.

    Article  PubMed  Google Scholar 

  61. Lauria F, Raspadori L, Benfenati D, et al. Biological markers and minimal residual disease in hairy cell leukemia. Leukemia. 1992;6(Suppl 4):149–51.

    PubMed  Google Scholar 

  62. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukemia by immunocytochemical detection of annexin a (ANXA 1). Lancet. 2004;363:1869–70.

    Article  CAS  PubMed  Google Scholar 

  63. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13:974–82.

    Article  CAS  PubMed  Google Scholar 

  64. Hakimian D, Tallman MS, Hogan DK, et al. Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia. J Clin Oncol. 1994;12:268–72.

    Article  CAS  PubMed  Google Scholar 

  65. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17:45–51.

    Article  CAS  PubMed  Google Scholar 

  66. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med. 1978;89:677–83.

    Article  CAS  PubMed  Google Scholar 

  67. Damaj G, Kuhnowski F, Marolleau JP, et al. Risk factors for severe infection in patients with hairy cell leukemia: a long term study of 73 patients. Eur J Haematol. 2009;83:246–50.

    Article  PubMed  Google Scholar 

  68. Vardiman JW, Golomb HM. Autopsy findings in hairy cell leukemia. Semin Oncol. 1984;11:370–80.

    CAS  PubMed  Google Scholar 

  69. Bourguin-Plonquet A, Rourad H, Roudot-Thoraval F, et al. Severe decrease in peripheral blood dendritic cell in hairy cell leukemia. Br J Haematol. 2002;116:595–7.

    Article  PubMed  Google Scholar 

  70. Hisada M, Chen BE, Jaffe ES, et al. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population based study. J Natl Cancer Inst. 2007;99:215–22.

    Article  PubMed  Google Scholar 

  71. Saven A, Burian C, Koziol J, et al. Long term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998;92:1918–26.

    CAS  PubMed  Google Scholar 

  72. Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood. 1994;83:2931–8.

    CAS  PubMed  Google Scholar 

  73. Wing YA, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20 year experience. Blood. 1998;92:1160–4.

    Google Scholar 

  74. Cornet E, Tomowiak C, Tanguy-Schmidt A, et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukemia. Br J Haematol. 2014;166(3):390–400.

    Article  CAS  PubMed  Google Scholar 

  75. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891–6.

    Article  PubMed  Google Scholar 

  76. Rosenberg JD, Burian C, Waalen J, et al. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014;123(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  77. Wolfe DW, Scopelliti JA, Boselli BD. Leukemic meningitis in a patient with hairy cell leukemia. A case report. Cancer. 1984;54:1085–7.

    Article  CAS  PubMed  Google Scholar 

  78. Dorsey JK, Penick GD. The association of hairy cell leukemia with unusual immunologic disorders. Arch Intern Med. 1982;142:902–3.

    Article  CAS  PubMed  Google Scholar 

  79. Juliusson G, Vitols S, Lilemark J, et al. Disease-related hypocholesterolemia in patients with hairy cell leukemia. Cancer. 1995;76:423–8.

    Article  CAS  PubMed  Google Scholar 

  80. Eklon KB, Hughes GR, Catovsky D. Hairy cell leukemia with polyarteritis nodosa. Lancet. 1979;2:280–2.

    Google Scholar 

  81. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukemia. Best Pract Res Clin Haematol. 2003;16:41–56.

    Article  CAS  PubMed  Google Scholar 

  82. Cawley JC, Burns GF, Hayhoe FG, et al. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukemia. Leuk Res. 1980;4:547–59.

    Article  CAS  PubMed  Google Scholar 

  83. Sainati L, Matutes E, Mulligan S, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood. 1990;76:157–62.

    CAS  PubMed  Google Scholar 

  84. Matutes E, Wotherspoon A, Brito-Babapulle V, et al. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15:184–6.

    Article  CAS  PubMed  Google Scholar 

  85. Hockley SL, Giannouli S, Morrilla A, et al. Insights into the molecular pathogenesis of hairy cell leukemia, hairy cell leukemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol. 2010;148(4):666–9.

    Article  PubMed  Google Scholar 

  86. Arons E, Kreitman RJ. Molecular variant of hairy cell leukemia with poor prognosis. Leuk Lymphoma. 2011;52(Suppl 2):99–102.

    Article  CAS  PubMed  Google Scholar 

  87. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Martin JL, Li C, Banks P, et al. Blastic variant of hairy-cell leukemia. Am J Clin Pathol. 1987;87:576–83.

    Article  Google Scholar 

  89. Machii T, Tokumine Y, Inoue R, et al. Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia. 1983;7:181–6.

    Google Scholar 

  90. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731–6.

    Article  CAS  PubMed  Google Scholar 

  91. Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994;83:1558–62.

    CAS  PubMed  Google Scholar 

  92. Pollack A. Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol. 2002;6:366–88.

    Article  Google Scholar 

  93. Galton DA, Wiltshaw GE, Catovsky D, et al. Prolymphocytic leukemia. Br J Haematol. 1974;27:7–23.

    Article  CAS  PubMed  Google Scholar 

  94. Dungarawalla M, Matutes E, Dearden E. Prolymphocytic leukemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol. 2008;80:469–76.

    Article  CAS  Google Scholar 

  95. Giblet ER, Anderson JE, Cohen F, et al. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2:1067–9.

    Article  Google Scholar 

  96. Cohen A, Hirschhorn R, Horowitz SD, et al. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978;75:472–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74:5677–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A. 1980;77:6865–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62:737–43.

    CAS  PubMed  Google Scholar 

  100. Piro LD, Carrerra CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117–21.

    Article  CAS  PubMed  Google Scholar 

  101. Else M, Dearden CE, Matutes E, et al. Long term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145:733–40.

    Article  CAS  PubMed  Google Scholar 

  102. Tallman MS, Hakimian D, Rademaker AW, et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long term follow-up of the northwestern experience. Blood. 1996;88:1954–9.

    CAS  PubMed  Google Scholar 

  103. Seymour J, Kurzrock R, Freireich EJ, et al. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906–11.

    CAS  PubMed  Google Scholar 

  104. Hoffman MA, Janson D, Rose E, et al. Treatment with hairy cell leukemia with cladribine: response, toxicity and long term follow-up. J Clin Oncol. 1997;15:1131–42.

    Article  Google Scholar 

  105. Jehn U, Bartl R, Dietzfelbinger H, et al. An update: 12 year follow up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18:1476–81.

    Article  CAS  PubMed  Google Scholar 

  106. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241–6.

    Article  CAS  PubMed  Google Scholar 

  107. Lopez RM, Da Silva C, Loscertales J, et al. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (CELLC). Leuk Lymphoma. 2014;55(5):1007–12.

    Article  CAS  Google Scholar 

  108. Hacioglu S, Bilen Y, Eser A, et al. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy. Hematol Oncol. 2015;33(4):192–8.

    Article  CAS  PubMed  Google Scholar 

  109. Somasundaram V, Purohit A, Aggarwal M, et al. Hairy cell leukemia: a decade long experience of North Indian Hematology Center. Indian J Med Paediatr Oncol. 2013;35(4):271–5.

    Google Scholar 

  110. Ruiz-Delgado GJ, Tarin-Arzaga LC, Alarcon-Urdaneta C, et al. Treatment of hairy cell leukemia: long-term results in a developing country. Hematology. 2012;17(3):140–3.

    Article  PubMed  Google Scholar 

  111. Golomb HM. Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol. 2008;26:2607–9.

    Article  PubMed  Google Scholar 

  112. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report, from the Polish Adult Leukemia Group (PALG) of a prospective randomized, multicenter trial. Blood. 2007;109:3672–5.

    Article  CAS  PubMed  Google Scholar 

  113. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115:21–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Saven A, Burian C, Adusumali J, et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999;93:2471–7.

    CAS  PubMed  Google Scholar 

  115. Spiers ASD, Parek SK. Complete remission in hairy cell leukemia achieved with pentostatin. Lancet. 1984;1:1080–1.

    Article  CAS  PubMed  Google Scholar 

  116. Flinn IW, Kopecky KJ, Foucar MK, et al. Long term follow-up of remission, duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000;96:2981–6.

    CAS  PubMed  Google Scholar 

  117. Cassileth PA, Cheuvart B, Spiers ASD, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991;9:243–6.

    Article  CAS  PubMed  Google Scholar 

  118. O’Dwyer PJ, Spiers ASD, Marsoni S. Association of severe and fatal infections and treatment with pentostatin. Cancer Treat Rep. 1986;70:1117–20.

    PubMed  Google Scholar 

  119. Johnston JB, Glazer RI, Pugh L, et al. The treatment of hairy-cell leukaemia with 2′-deoxycoformycin. Br J Haematol. 1986;63:525–34.

    Article  CAS  PubMed  Google Scholar 

  120. Smalley RV, Connors J, Tuttle RL, et al. Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia. Am J Hematol. 1992;41:13–8.

    Article  CAS  PubMed  Google Scholar 

  121. Zakarija A, Peterson LC, Tallman M, et al. Splenectomy and treatments of historical interest. Best Pract Res Clin Haematol. 2003;16:57–68.

    Article  PubMed  Google Scholar 

  122. Mintz U, Golomb HM. Splenectomy as initial therapy in twenty six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res. 1979;39:2366–70.

    CAS  PubMed  Google Scholar 

  123. Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood. 1983;61:349–52.

    CAS  PubMed  Google Scholar 

  124. Ratain MJ, Vardiman JW, Barker CM. Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer. 1988;62:2420–4.

    Article  CAS  PubMed  Google Scholar 

  125. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma. 1995;13:307–16.

    Article  Google Scholar 

  126. Stiles GM, Stanco LM, Saven A, et al. Splenectomy for hairy cell leukemia in pregnancy. J Perinatol. 1998;18:200.

    CAS  PubMed  Google Scholar 

  127. Vendantham S, Gamliel H, Golomb HM. Mechanisms of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res. 1992;52:1056–66.

    Google Scholar 

  128. Quesada JR, Reuben J, Manning JT, et al. Alpha-interferon for induction of remission in hairy cell leukemia. N Engl J Med. 1984;310:15–8.

    Article  CAS  PubMed  Google Scholar 

  129. Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986;68:493–7.

    CAS  PubMed  Google Scholar 

  130. Golomb HM, Jacobs A, Fefer A, et al. Alpha-2 interferon therapy for hairy cell leukemia: a multicenter study of 64 patients. J Clin Oncol. 1986;4:900–5.

    Article  CAS  PubMed  Google Scholar 

  131. Ratain MJ, Golomb HM, Vardiman JW, et al. Relapse after interferon-alpha-2b for hairy cell leukemia: analysis of prognostic variables. J Clin Oncol. 1988;6:1714–21.

    Article  CAS  PubMed  Google Scholar 

  132. Damasio EE, Masoudi CM, Spriano IA, et al. Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long term follow-up analysis. Eur J Haematol. 2000;64:47–52.

    Article  CAS  PubMed  Google Scholar 

  133. Capnist G, Federico M, Chisesi T, et al. Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia. Leuk Lymphoma. 1994;14:457–64.

    Article  CAS  PubMed  Google Scholar 

  134. Hoffmen MA. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases. Med Oncol. 2011;28:1537.

    Article  CAS  Google Scholar 

  135. Steis RG, Marcon L, Clark J, et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood. 1988;71:1304–9.

    CAS  PubMed  Google Scholar 

  136. Naik R, Saven A. My treatment approach to hairy cell leukemia. Mayo Clin Proc. 2012;87(1):67–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Ellison DJ, Sharp RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 1994;84:4310–5.

    CAS  PubMed  Google Scholar 

  138. Arons E, Margulies I, Sorbara L, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res. 2006;12:2804–11.

    Article  CAS  PubMed  Google Scholar 

  139. Bengio R, Narbaitz MI, Sarmiento MA, et al. Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia. Haematologica. 2000;85:1227–9.

    CAS  PubMed  Google Scholar 

  140. Hakimian D, Tallman MS, Kiley C, et al. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 1993;82:1798–802.

    CAS  PubMed  Google Scholar 

  141. Wheaton S, Tallman MS, Hakimian D. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood. 1996;87:1556–60.

    CAS  PubMed  Google Scholar 

  142. Matutes E, Meeus P, McLennan K, et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol. 1997;98:375–83.

    Article  CAS  PubMed  Google Scholar 

  143. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia. 1994;8:1153–6.

    CAS  PubMed  Google Scholar 

  144. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107:4658–62.

    Article  CAS  PubMed  Google Scholar 

  145. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukemia. Eur J Haematol. 2004;73:412–7.

    Article  CAS  PubMed  Google Scholar 

  146. Sigal DS, Sharpe R, Burian C, et al. Very long term eradication of minimal residual disease in patients with hairy cell leukemia following a single course of cladribine. Blood. 2010;115:1893–6.

    Article  CAS  PubMed  Google Scholar 

  147. Forconi F, Sozzi E, Cencini E, et al. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine with more aggressive behavior. Blood. 2009;114:4696–702.

    Article  CAS  PubMed  Google Scholar 

  148. Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2-deoxycoformycin. Ann Intern Med. 1993;119(4):278–83.

    Article  CAS  PubMed  Google Scholar 

  149. Kreitman RJ, Fitzgerald DJP, Pastan I, et al. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma. 2009;50(Suppl 1):32–7.

    Article  CAS  PubMed  Google Scholar 

  150. Hagberg H. Chimeric monoclonal anti-CD20 antibody (rituximab)—an effective treatment for a patient with relapsing hairy cell leukemia. Med Oncol. 1999;14:221–2.

    Article  Google Scholar 

  151. Nieva J, Bethel K, Saven A. Phase II study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102:810–3.

    Article  CAS  PubMed  Google Scholar 

  152. Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102:3906–11.

    Article  CAS  PubMed  Google Scholar 

  153. Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015;28(4):217–29.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Ravandi F, O’Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011;118(14):3818–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Leclerc M, Suarez F, Noel MP, et al. Rituximab therapy for hairy cell leukemia: a restrospective study of 41 cases. Ann Hematol. 2015;94(1):89–95.

    Article  CAS  PubMed  Google Scholar 

  156. Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood. 2012;119(9):1988–91.

    Article  CAS  PubMed  Google Scholar 

  157. Kreitmaan RJ, Wilson W, Calvo KR, et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013;19(24):6873–81.

    Article  CAS  Google Scholar 

  158. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013;31(20):e351–2.

    Article  PubMed  Google Scholar 

  159. Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013;98(2):e20–2.

    Article  PubMed  PubMed Central  Google Scholar 

  160. Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370(3):286–8.

    Article  CAS  PubMed  Google Scholar 

  161. Dietrich S, Hullein J, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013;31(19):e300–3.

    Article  CAS  PubMed  Google Scholar 

  162. Tiacci E, Park JH, De Carolis SS, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88.

    Article  PubMed  CAS  Google Scholar 

  164. Pettirossi V, Santi A, Imperi E, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125(8):1207–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345(4):241–7.

    Article  CAS  PubMed  Google Scholar 

  166. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase 1 trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23(27):6719–29.

    Article  CAS  PubMed  Google Scholar 

  167. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27(18):2983–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Kreitman RJ, Tallman MS, Robak T, et al. Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15):1822–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Kreitmen RJ, Wilson WH, White JD, et al. Phase 1 trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18(8):1622–36.

    Article  Google Scholar 

  171. Sasaki M, Sugimoto K, Mori T, et al. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol. 2008;119(1):48–53.

    Article  PubMed  Google Scholar 

  172. Fietz T, Rieger K, Schmittel A, Thiel E, Knauf W. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J. 2004;5(5):451–2.

    Article  CAS  PubMed  Google Scholar 

  173. Kreitman RJ, Arons E, Stetler-Stevenson M, et al. Response of hairy cell leukemia to bendamustine. Leuk Lymphoma. 2011;52(6):1153–6.

    Article  CAS  PubMed  Google Scholar 

  174. Burotto M, Stetler-Stevenson M, Arons E, et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res. 2013;19(22):6313–21.

    Article  CAS  PubMed  Google Scholar 

  175. Randomized Phase II trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia. https://clinicaltrials.gov/ct2/show/NCT01059786.

  176. Sivina M, Kreitman RJ, Arons E, et al. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014;166(2):177–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. Jones JA, Andritsos LA, Lucas DM, et al. Preliminary safety and efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL). J Clin Oncol. 2014;32(5 Suppl):abstract 7063.

    Google Scholar 

  178. Ibrutinib in treating patients with relapsed hairy cell leukemia. https://clinicaltrials.gov/ct2/show/NCT01841723.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA, 92037, USA

    Sonia Ali M.D. & Alan Saven M.D.

Authors
  1. Sonia Ali M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan Saven M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonia Ali M.D. .

Editor information

Editors and Affiliations

  1. Cancer Research Foundation, Chappaqua, New York, USA

    Peter H. Wiernik

  2. Cancer Research Foundation, Chappaqua, New York, USA

    Janice P. Dutcher

  3. Department of Hematology, Mayo Clinic Department of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Cite this chapter

Ali, S., Saven, A. (2018). Hairy Cell Leukemia. In: Wiernik, P., Dutcher, J., Gertz, M. (eds) Neoplastic Diseases of the Blood. Springer, Cham. https://doi.org/10.1007/978-3-319-64263-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64263-5_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64262-8

  • Online ISBN: 978-3-319-64263-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation